<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601975</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-17-III</org_study_id>
    <nct_id>NCT03601975</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III randomized controlled multi-center trial comparing anlotinib plus&#xD;
      Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients&#xD;
      with recurrent/metastatic Nasopharyngeal Carcinoma, in order to verify the efficacy and&#xD;
      security of anlotinib in mNPC patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>12months</time_frame>
    <description>Progeression free survival is calculated from randomization to disease progeression or death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>anlotinib plus Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo plus Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/Cisplatin</intervention_name>
    <description>gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle</description>
    <arm_group_label>anlotinib plus Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_label>placebo plus Gemcitabine/Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed of the investigational nature of this study and give written informed consent&#xD;
&#xD;
          2. Histologically or cytologically confirmed nasopharyngeal carcinoma, tumor staged as&#xD;
             IVB (according to the 8th AJCC edition) or recurrent tumor nott suitable for local&#xD;
             treatment.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to1, life&#xD;
             expectancy of at least 12 weeks.&#xD;
&#xD;
          4. Antitumor therapy naive for recurrent or metastatic nasopharyngeal carcinoma&#xD;
&#xD;
          5. Completed radiotherapy for local tumor 4 weeks before the enrollment&#xD;
&#xD;
          6. Measurable disease other than brain metastasis based on Response Evaluation Criteria&#xD;
             in Solid Tumors (RECIST) version 1.1&#xD;
&#xD;
          7. Adequate organ system function, defined as follows:&#xD;
&#xD;
               1. ANC ≥1.5×109/L, PLT ≥100×109/L, Hb）≥90g /L;&#xD;
&#xD;
               2. TBIL ≤ 1.5×ULN；Aminopherases (ALT and AST) ≤ 2.5 × ULN (without liver metastasis)&#xD;
                  or ≤ 5.0 × ULN (with liver metastasis), Creatinine ≤ 1.5 × ULN or creatinine&#xD;
                  clearance ≥ 50 ml/min;&#xD;
&#xD;
               3. Urine protein &lt; ++，or urine protein ≥ ++ concomitant with content of -hour&#xD;
                  urinary protein &lt;1.0 g;&#xD;
&#xD;
               4. INR≤1.5×ULN, APTT≤1.5×ULN;&#xD;
&#xD;
               5. LVEF ≥50%;&#xD;
&#xD;
          8. Women who are not of child-bearing potential, and women of child-bearing potential who&#xD;
             have a negative serum or urine pregnancy test prior to initial trial treatment, and&#xD;
             who agree to use adequate contraceptive measures during the study; Men with partners&#xD;
             of childbearing potential willing to use adequate contraceptive measures during the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a previous malignancy within the past 5 years (other than curatively&#xD;
             treated in situ carcinoma of the cervix, non-melanoma skin cancer and superficial&#xD;
             bladder carcinoma).&#xD;
&#xD;
          2. Allergic to anotinib or the chemotherapeutic agents involved in this trial;&#xD;
&#xD;
          3. Supposed to receive locally treatment (except for those with symptomatic bone&#xD;
             metastases receive appropriate local doses radiotherapy which does not affect the&#xD;
             hemogram)&#xD;
&#xD;
          4. Patients that have received definitive radiotherapy, adjuvant chemotherapy or&#xD;
             cocurrent chemoradiotherapy for stage I-IVA and developed recurrent disease within 6&#xD;
             months;&#xD;
&#xD;
          5. Patients that have previously received target therapies;&#xD;
&#xD;
          6. Patients that have previously received immunotherapy (i.e.,interferon, or IL-2 ) 28&#xD;
             days before randomization or within 5 half-life of the drug.&#xD;
&#xD;
          7. Patients that have previously received immunosupressive drugs (i.e., Corticosteroids,&#xD;
             cyclophosphamide, azathioprine, methotrexate, thalidomide or TNF-α)&#xD;
&#xD;
          8. Symptomatic CNS metastasis (i.e. encephaledema, hormone intervention, or brain&#xD;
             metastasis progression)&#xD;
&#xD;
          9. Patients currently have bleeding tendency, including but not limited to&#xD;
             gastrointestinal bleeding, nasal bleeding, hemoptysis, and persistent bleeding or&#xD;
             coagulopathy;&#xD;
&#xD;
         10. Hemoptysis (defined as coughing out or spitting out ≥ 1 teaspoon of blood or small&#xD;
             blood clots or hemoptysis without sputum) within 28 days before randomization, not&#xD;
             including bloody sputum.&#xD;
&#xD;
         11. Radiograph (within 28 days before randomization) showed that the tumor surrounded&#xD;
             important blood vessels, and the investigators determined that entering the study&#xD;
             would cause bleeding risk;&#xD;
&#xD;
         12. Subjects have any of the following severe acute complications:&#xD;
&#xD;
               1. Unstable angina and/or congestive heart failure or vascular disease (eg, aortic&#xD;
                  aneurysm requires surgically repaired or peripheral venous thromboembolism)&#xD;
                  requiring hospitalization within 12 months, or other cardiac impairments&#xD;
                  (eg,uncontrolled arrhythmias) determined by the investigator, which may affect&#xD;
                  the evaluation of drug safety; Myocardial infarction or ischemia with ST&#xD;
                  elevation ≥ 2 mm indicated by ECG;&#xD;
&#xD;
               2. Arterial thromboembolism, venous thromboembolism in grade 3 or higher (according&#xD;
                  to NCI-CTCAE), transient ischemic attack (TIA), cerebral vascular accident (CVA),&#xD;
                  transmural myocardial infarction ( MI), hypertensive crisis or hypertensive&#xD;
                  encephalopathy within 24weeks;&#xD;
&#xD;
               3. Chronic Obstructive Pulmonary Disease (COPD) or other respiratory diseases&#xD;
                  requiring hospitalization within 28 days before randomization;&#xD;
&#xD;
               4. Abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or&#xD;
                  acute gastrointestinal bleeding within 24 weeks before randomization;&#xD;
&#xD;
               5. Esophageal and gastric varices, unhealed ulcers, unhealed wounds or fracture&#xD;
                  within 24 weeks before randomization;&#xD;
&#xD;
               6. Pulmonary infections and/or acute bacterial or fungal infections requiring&#xD;
                  intravenous antibiotic therapy&#xD;
&#xD;
               7. Clinical jaundice and/or coagulation disorders caused by liver dysfunction;&#xD;
&#xD;
               8. Minor surgical procedures (including catheterization, excluding peripheral&#xD;
                  venipuncture central vena catheterization) within 2 days of randomization;&#xD;
&#xD;
         13. The virological test indicates that either of the following 28 days before&#xD;
             randomization&#xD;
&#xD;
               1. HBsAg positive and HBV DNA ≥ 1 × 103 copies/L;&#xD;
&#xD;
               2. Anti-HCV positive&#xD;
&#xD;
               3. HIV positive&#xD;
&#xD;
         14. Participation of an anti-tumor clinic trial within 28 days before randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>651 Dongfeng Road East, Yuexiu District, Guanzhou, P.R. China</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, doctor</last_name>
      <phone>020-87343458</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

